BioAtla (BCAB) to Release Quarterly Earnings on Thursday

BioAtla (NASDAQ:BCAB) is expected to be announcing its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

BioAtla (NASDAQ:BCAB) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.02). On average, analysts expect BioAtla to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

BioAtla Price Performance

NASDAQ BCAB opened at $0.70 on Thursday. BioAtla has a 12 month low of $0.24 and a 12 month high of $2.53. The firm has a market capitalization of $40.99 million, a PE ratio of -0.63 and a beta of 1.03. The company’s 50 day simple moving average is $0.66 and its 200 day simple moving average is $0.49.

Wall Street Analysts Forecast Growth

BCAB has been the topic of a number of research analyst reports. JMP Securities reiterated a “market perform” rating on shares of BioAtla in a research note on Wednesday, August 13th. Citizens Jmp lowered shares of BioAtla from an “outperform” rating to a “market perform” rating in a research note on Wednesday, August 13th. Wall Street Zen upgraded shares of BioAtla to a “sell” rating in a research note on Saturday, September 6th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research note on Tuesday, October 14th. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, BioAtla currently has a consensus rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BioAtla stock. Acadian Asset Management LLC boosted its holdings in BioAtla, Inc. (NASDAQ:BCAB) by 968.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,690,110 shares of the company’s stock after buying an additional 1,531,994 shares during the quarter. Acadian Asset Management LLC owned 2.89% of BioAtla worth $585,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 77.23% of the company’s stock.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.